39 related articles for article (PubMed ID: 29036906)
1. A fluorescence-based assay for p38α recruitment site binders: identification of rooperol as a novel p38α kinase inhibitor.
Li J; Kaoud TS; LeVieux J; Gilbreath B; Moharana S; Dalby KN; Kerwin SM
Chembiochem; 2013 Jan; 14(1):66-71. PubMed ID: 23225637
[TBL] [Abstract][Full Text] [Related]
2. Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3.
Ansideri F; Macedo JT; Eitel M; El-Gokha A; Zinad DS; Scarpellini C; Kudolo M; Schollmeyer D; Boeckler FM; Blaum BS; Laufer SA; Koch P
ACS Omega; 2018 Jul; 3(7):7809-7831. PubMed ID: 30087925
[TBL] [Abstract][Full Text] [Related]
3. Special Issue: Kinase inhibitors.
Koch P; Laufer S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30037125
[No Abstract] [Full Text] [Related]
4. Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds.
Kong TT; Zhang CM; Liu ZP
Curr Med Chem; 2013; 20(15):1997-2016. PubMed ID: 23317165
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold.
Scior T; Domeyer DM; Cuanalo-Contreras K; Laufer SA
Curr Med Chem; 2011; 18(10):1526-39. PubMed ID: 21428890
[TBL] [Abstract][Full Text] [Related]
6. From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors.
Heider F; Haun U; Döring E; Kudolo M; Sessler C; Albrecht W; Laufer S; Koch P
Molecules; 2017 Oct; 22(10):. PubMed ID: 29036906
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
[TBL] [Abstract][Full Text] [Related]
8. Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.
Heider F; Ansideri F; Tesch R; Pantsar T; Haun U; Döring E; Kudolo M; Poso A; Albrecht W; Laufer SA; Koch P
Eur J Med Chem; 2019 Aug; 175():309-329. PubMed ID: 31096153
[TBL] [Abstract][Full Text] [Related]
9. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
Koch P; Laufer S
J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
[TBL] [Abstract][Full Text] [Related]
10. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
[TBL] [Abstract][Full Text] [Related]
11. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease.
Lee JK; Kim NJ
Molecules; 2017 Aug; 22(8):. PubMed ID: 28767069
[TBL] [Abstract][Full Text] [Related]
13. Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.
Günther M; Juchum M; Kelter G; Fiebig H; Laufer S
Angew Chem Int Ed Engl; 2016 Aug; 55(36):10890-4. PubMed ID: 27466205
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.
Koch DA; Silva RB; de Souza AH; Leite CE; Nicoletti NF; Campos MM; Laufer S; Morrone FB
Rheumatology (Oxford); 2014 Mar; 53(3):425-32. PubMed ID: 24241037
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
